|
Cardiology
Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
Chang-Wook Nam, Dong-Soo Kim, Jianyong Li, Marie T. Baccara-Dinet, Ivy Li, Ji-Hyun Kim, Chong-Jin Kim
Korean J Intern Med. 2019;34(6):1252-1262. Published online September 1, 2018
Background/Aims: Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), is not yet well established in the Korean population. We assessed them in ODYSSEY-KT through the pre-specified Korean subanalysis.
Methods: In the ODY..
|
|
|
Rheumatology
Factors related to outcomes in lupus-related protein-losing enteropathy
Doo-Ho Lim, Yong-Gil Kim, Seung-Hyeon Bae, Soomin Ahn, Seokchan Hong, Chang-Keun Lee, Bin Yoo
Korean J Intern Med. 2015;30(6):906-912. Published online October 30, 2015
Background/Aims: Protein-losing enteropathy (PLE), characterized by severe hypoalbuminemia and peripheral edema, is a rare manifestation of systemic lupus erythematosus. This present study aimed to identify the distinctive features of lupus-related PLE and evaluate the factors related to the treatme..
|
|
|
Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia
Jong-Seon Park, Young-Jo Kim, Ji-Yong Choi, Yoon-Nyun Kim, Teck-Jong Hong, Dong-Soo Kim, Ki-Young Kim, Myung-Ho Jeong, Jei-Keon Chae, Seok-Kyu Oh, In-Whan Seong
Korean J Intern Med. 2010;25(1):27-35. Published online February 26, 2010
Background/AimsThis multicenter, open-labeled, randomized trial was performed to compare the effects of rosuvastatin 10 mg and atorvastatin 10 mg on lipid and glycemic control in Korean patients with nondiabetic metabolic syndrome. MethodsIn tot..
|
|
|
